Pediatric oncology has seen a major breakthrough in early 2026 with the adaptation of oncolytic viruses for childhood cancers, specifically "diffuse midline gliomas" and other rare brain tumors. Because these viruses are highly targeted and lack the "long-term developmental toxicity" of radiation and heavy chemotherapy, they are considered an ideal choice for the developing brains of children....